DuoCort completes enrolment for pivotal phase II-III adrenal insufficiency trial
The pivotal phase II-III trial is a controlled study assessing the pharmacokinetics, safety and tolerability of once-daily DuoCort in comparison to conventional thrice-daily oral hydrocortisone therapy in patients with primary adrenal insufficiency (Addison's disease). The trial commenced in August 2007 and is being conducted at five University endocrinology clinics.
The patients who have so far completed the run-in phase and who have been randomized to DuoCort are all reported to be doing well. The primary aim is to compare bioavailability between once-daily DuoCort dual-release hydrocortisone tablets and conventional hydrocortisone replacement therapy. Secondary aims include comparing short- and long-term safety, tolerability and efficacy of DuoCort to conventional replacement therapy and assessing the safety of using DuoCort as "rescue therapy" during minor intercurrent illnesses. Interim analysis is planned six months after inclusion of the last patient, with data expected to be available in Q3 2008.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.